Eric Vivier

All filings by Eric Vivier on record concern Innate Pharma, in the capacity of senior executive. In total, 5 filings cover trades dated from 27 January 2022 to 31 December 2024.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

On 17 January 2025 came the latest disclosure, a share grant in Innate Pharma. Between a trade and the moment it shows up on AMF, the median delay is 6 days. The regulation allows three business days to notify a trade (MAR article 19). Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.